Skip to main content
Egyptian Liver Journal
Fig. 5 | Egyptian Liver Journal

Fig. 5

From: Baseline and recurrent exposure to the standard dose of artemisinin-based combination therapies (ACTs) induces oxidative stress and liver damage in mice (BALB/c)

Fig. 5

(A) Plasma Alkaline Phosphatase (ALP) Activities (B) Liver Alkaline Phosphatase (ALP) activities (C) Plasma Bilirubin Concentration (D) Liver Bilirubin Concentration; of mice after the 1st, 2nd, 3rd and 6th treatment with either Artemether/Lumefantrine (A/L) or Artesunate/Amodiaquine (A/A) compared to the control group. Values are expressed as mean ± SEM (n = 3), and a, b, and c indicate significant differences at p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the corresponding control groups

Back to article page